Business Wire

NY-QUARTILE

13.12.2021 19:02:04 CET | Business Wire | Press release

Share
Quartile Acquires Sidecar to Form Largest Cross-Channel E-Commerce Advertising Platform

Quartile , the leading ad optimization platform for top e-commerce marketplace sellers, today announced it has acquired Sidecar , a performance marketing technology provider for e-commerce retailers and brands that works across all major advertising platforms , including Google, Microsoft Bing, Facebook, Instagram, and Amazon.

The two companies will combine under the Quartile name, growing the brand into the world’s largest cross-channel e-commerce advertising platform. Both platforms apply machine-learning and natural-language processing to provide data-driven strategies and best practices to brand marketers while also offering best-in-class reporting and ad management.

Quartile expects the acquisition to double its amount of advertising spend under management across all platforms to $2 billion in 2021. Unilever, Burt’s Bees and Thrasio are among the more than 5,000 brands currently using the platforms on e-commerce channels like Amazon, Google, Instacart, Walmart, Facebook and Shopify. The combined company will have clients across 26 countries.

"By combining Sidecar's best-in-class solution and expertise managing campaigns for DTC e-commerce merchants with our proprietary AI-driven analytics and optimization platform, we will create the most comprehensive and powerful e-commerce suite," said Daniel Knijnik, co-founder and CEO at Quartile. “The two companies’ complementary businesses, products and relationships will offer unrivaled benefits for our combined customers, employees and other stakeholders across a diverse set of markets.”

"Retail marketers and small businesses are up against great odds when it comes to being seen in online marketplaces. Only 0.1% of products account for around 80% of the sales on e-commerce marketplaces, so brands recognize they need a holistic solution to help them compete in all marketplaces and direct-to-consumer websites,” added Knijnik.

Both Quartile and Sidecar have witnessed exponential growth in recent years as fiercer competition among e-commerce merchants has led to increased advertising spend. Amazon is predicted to grow its ad revenue to $24.47 billion by the end of 2021, an increase of 55.5% year over year, closing the gap as the world's third-largest ad network after Google and Facebook (whose ad revenues grew 34% and 43% , respectively). The platforms provide e-commerce marketers with a critical edge in this fast growing industry.

"We share a passion with the Quartile team for helping small businesses and large retailers grow their exposure, shopping audience, and brands across channels," said Andre Golsorkhi, founder and CEO of Sidecar. "This acquisition is the ultimate example of how we continue to dig in for our customers as their challenges become more complex. By combining the aptitudes and technologies of Sidecar and Quartile, we are continuing to ensure the performance marketing excellence that retailers rely on us for.”

Terms of the acquisition were not disclosed. The combined businesses will comprise a team of more than 300 personnel. Rockbridge Growth Equity, a Detroit-based private equity firm which originally invested a minority stake in Quartile in September of last year, will remain the lead institutional investor in the transaction. Existing Sidecar shareholders will also own a significant stake of the post-acquisition Quartile entity. Investment Bank Canaccord Genuity served as the exclusive financial advisor to Quartile and Rockbridge in connection with the transaction.

“We are thrilled to be partnering with the Sidecar team,” said Kevin Prokop, founder and managing partner at Rockbridge. “The Sidecar team has built an exceptional business. We believe the combination of Quartile and Sidecar creates a distinctive company that is uniquely positioned to capture the exciting opportunities in the e-commerce marketing industry.”

About Quartile:

Founded in 2016, Quartile is an artificial intelligence and machine learning-powered ad optimization platform for leading e-commerce marketplace sellers, such as Amazon, Walmart.com, and Instacart. Quartile’s advertising technology uses proprietary technology and six patented algorithms to make real-time decisions based on accurate data for improved performance and growth. The Quartile platform is an easy-to-use dashboard that equips sellers with the tools to manage their retail media in every marketplace, enabling them to optimize campaigns at the product level to maximize sales, lower the advertising cost of sale (ACoS), and improve margins. For more information visit: www.quartile.com .

About Sidecar:

Sidecar offers performance marketing excellence to retailers and brands. Sidecar’s advanced technology and proprietary data, combined with years of performance marketing expertise, help its customers unlock the full potential of today’s most powerful search, shopping, social, and marketplace channels. For more information, visit: getsidecar.com

Link:

ClickThru

Social Media:

https://www.facebook.com/quartiledigital

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye